Avutometinib-defactinib trial in mesonephric gynecologic cancer stays active, not recruiting
A Memorial Sloan Kettering-sponsored Phase 2 study combining avutometinib and defactinib for mesonephric gynecologic cancer remains active but closed to new enrollment, per an October 8, 2026 registry update.
This week's only update concerns a single ongoing Verastem-linked trial.
- This single-arm Phase 2 study is testing avutometinib (VS-6766) combined with defactinib in people with advanced or recurrent mesonephric gynecologic cancer, sponsored by Memorial Sloan Kettering Cancer Center with Verastem, Inc. as a collaborator.1 The trial's status is active, not recruiting, with an actual start date of March 15, 2023, and an estimated primary completion in March 2027.1 Enrollment reached 40 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.